Welcome to LookChem.com Sign In|Join Free
  • or
4-Pyridinamine, N-(1-ethylpropyl)-6-methyl-3-nitro-2-(2,4,6-trimethylphenoxy)- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

175140-02-0

Post Buying Request

175140-02-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

175140-02-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 175140-02-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,5,1,4 and 0 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 175140-02:
(8*1)+(7*7)+(6*5)+(5*1)+(4*4)+(3*0)+(2*0)+(1*2)=110
110 % 10 = 0
So 175140-02-0 is a valid CAS Registry Number.

175140-02-0Relevant academic research and scientific papers

Corticotropin releasing factor antagonists

-

, (2008/06/13)

Corticotropin-releasing factor (CRF) antagonists having the formulae wherein the dashed lines, A, B, Y, Z, G, R3, R4, R5, R6, R16 and R17 are as defined in the application, and processes fo

Use of CRF antagonists and renin-angiotensin system inhibitors

-

, (2008/06/13)

The present invention relates to compositions and methods of achieving a therapeutic effect including, but not limited to, the treatment of congestive heart failure or hypertension in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist and a renin-angiotensin system (RAS) inhibitor.

QT dispersion and heart rate variability improvement with CRF antagonists to prevent sudden death

-

, (2008/06/13)

A method of preventing sudden death which comprises administering to a mammal, including a human, a therapeutically effective amount of a corticotropin releasing factor antagonist.

New uses for corticotropin releasing factor antagonists

-

, (2008/06/13)

A method of treating, preventing or inhibiting a disorder selected from the group consisting of cardiovascular or heart related diseases such as stroke, hypertension, tachycardia, and congestive heart failure, osteoporosis, premature birth, psychosocial dwarfism, stress-induced fever, ulcer, diarrhea, post-operative ileus, and colonic hypersensitivity associated with psychopathological disturbance and stress, comprising administering to a mammal, including a human, in need of such treatment a therapeutically effective amount of a compound of the formula or pharmaceutically acceptable salt thereof, wherein A, B, D, E, Y, Z, R3, R4, and R5 are as defined herein.

CORTICOTROPIN RELEASING FACTOR ANTAGONISTS

-

, (2008/06/13)

Corticotropin-releasing factor (CRF) antagonists having formulae (I), (II) or (III) wherein the dashed lines, A, B, Y, Z, G, R. sub.3, R. sub.4, R. sub.5, R 6, R 16 and R 17 are as defined in the description, and processes for preparing them. These compou

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 175140-02-0